Roy D. Baynes
Director · 7 filings · Latest: May 19, 2026
Natera, Inc.
Nurix Therapeutics, Inc.
Travere Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
TVTX | Roy D. Baynes | Director | May 19, 2026 | Grant/Award | $0.00 | 4,000 | — | 41,500 | |
TVTX | Roy D. Baynes | Director | May 5, 2026 | Sale | $46.65 | 4,500 | $209.9K | 37,500 | |
TVTX | Roy D. Baynes | Director | May 5, 2026 | Option Exercise | $18.27 | 4,500 | $82.2K | 42,000 | |
TVTX | Roy D. Baynes | Director | May 1, 2026 | Sale | $44.22 | 9,750 | $431.1K | 37,500 | |
TVTX | Roy D. Baynes | Director | May 1, 2026 | Option Exercise | $6.82 | 9,750 | $66.5K | 47,250 | |
NTRA | Roy D. Baynes | Director | Apr 24, 2026 | Grant/Award | — | 83 | — | 18,512 | |
TVTX | Roy D. Baynes | Director | Apr 14, 2026 | Sale | $41.29 | 32,750 | $1.4M | 37,500 | |
TVTX | Roy D. Baynes | Director | Apr 14, 2026 | Option Exercise | $17.60 | 32,750 | $576.3K | 70,250 | |
TVTX | Roy D. Baynes | Director | Apr 6, 2026 | Sale | $33.00 | 10,000 | $330.0K | 37,500 | |
TVTX | Roy D. Baynes | Director | Apr 6, 2026 | Option Exercise | $26.52 | 10,000 | $265.2K | 47,500 |